[CLAIMS]

[Claim 1] A compound which is (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.$0^{4,8}$.$0^{26,30}$]pentatetracont-42-ene-23,1'-cyclobutane]-17-carboxamide.

[Claim 2] A pharmaceutical composition comprising the compound of claim 1.

[Claim 3] Use of a pharmaceutical composition in the manufacture of a medicament for selectively inhibiting KRAS in a subject, wherein the composition comprises the compound according to claim 1.

[Claim 4] Use of a pharmaceutical composition in the manufacture of a medicament for treating or preventing cancer in a subject, wherein the composition comprises an effective amount of the compound according to claim 1.

[Claim 5] The use according to claim 4, wherein the cancer is lung cancer.

[Claim 6] The use according to claim 4, wherein the subject is a human.

[Claim 7] A solvate of (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.$0^{4,8}$.$0^{26,30}$]pentatetracont-42-ene-23,1'-cyclobutane]-17-carboxamide.

[Claim 8] The solvate according to claim 7, which is a hydrate.

[Claim 9] A pharmaceutical composition comprising the solvate of claim 7 or 8.

[Claim 10] Use of a pharmaceutical composition in the manufacture of a medicament for selectively inhibiting KRAS in a subject, wherein the composition comprises the solvate according to claim 7 or 8.

[Claim 11] Use of a pharmaceutical composition in the manufacture of a medicament for treating or preventing cancer in a subject, wherein the composition comprises an effective amount of the solvate according to claim 7 or 8.

[Claim 12] The use according to claim 11, wherein the cancer is lung cancer.

[Claim 13] The use according to claim 11, wherein the subject is a human.

[Claim 14] A salt of (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.$0^{4,8}$.$0^{26,30}$]pentatetracont-42-ene-23,1'-cyclobutane]-17-carboxamide, or a solvate thereof.

[Claim 15] A pharmaceutical composition comprising the salt of claim 14, or a solvate thereof.

[Claim 16] Use of a pharmaceutical composition in the manufacture of a medicament for selectively inhibiting KRAS in a subject, wherein the composition comprises the salt of claim 14, or a solvate thereof.

[Claim 17] Use of a pharmaceutical composition in the manufacture of a medicament for treating or preventing cancer in a subject, wherein the composition comprises an effective amount of the salt of claim 14, or a solvate thereof.

[Claim 18] The use according to claim 17, wherein the cancer is lung cancer.

[Claim 19] The use according to claim 17, wherein the subject is a human.